Project #1
DESCRIPTION
Successful NIH - FDA Phase I Grant Study – UW Global Health Pill Tracking Mobile AppTruMedicines of Seattle, WA funded by NIH-FDA grant# IR43FD006302
When
January 2018
Who
David Prokop CEO
Successful NIH - FDA Phase I Grant Study – UW Global Health Pill Tracking Mobile AppTruMedicines of Seattle, WA funded by NIH-FDA grant# IR43FD006302 to create NIH Bayh-Dole Act patented mobile app MyCap-TruMedicines to log self-reported health measures and automatically track drug therapy adherence. Patient drug adherence is securely logged to the healthcare providers patient history (REDCap) account. A monitoring physician can quickly and easily check daily status of COVID19 patients remotely without risk of exposure. Healthcare staff can respond to all needs of the patient in real-time monitoring to give real-time consulting from their patient dashboard webpage. Medical Device Exempt Cures Act Sec 520(o)(1)(A) FD&C Act (D). FDA Class I exempt CFR 21 § 890.5050-NXB 2799, GMP exempt.Daily activity assist device https://doi.org/10.1177%2F1357633X211004321US Patents# 8,888,005; 9,152,913; 9,477,810; CA Pat 2,858,923-Marked Pharmaceutical Tablets NIH-FDA Study. “Pill Identification using a Mobile Phone App for Assessing Medication Adherence and Post-Market Drug Surveillance.” ArXiv abs/2004.11479 (2020): n. page.TruMedicines Lab 218, UWash., Fluke Hall, Box 354950, 4000 Mason Road, Seattle, WA 98195David@TruMedicines.com
Grow your Medical Practice
Today is the day to build you Medical Practice,
1) reach more patients with Telemedicine,
2) Check in with patients with automatic remote monitoring.
3) Video Calling allows Staff members to One-on-One TeleMedicine sessions.
Start Now